No spam. Unsubscribe anytime.
GH Secretagogue Study Kit
Three distinct GH secretagogue mechanisms studied in published endocrine research
Targets the growth hormone axis through three complementary receptor systems described in published endocrine literature. CJC-1295 (no DAC) provides GHRH-analog pulsatile release, Ipamorelin offers selective ghrelin-receptor activation (published data shows minimal cortisol/prolactin elevation), and MK677 adds oral GH secretagogue coverage with sustained IGF-1 elevation across 24-hour periods in peer-reviewed studies.
$15.73/vial avg · 9 vials total · Everything you need
Research Protocol Timeline
Week-by-week observations documented in published peer-reviewed studies
GH Secretagogue Loading & Sleep Architecture
- Published research observed acute GH secretion peaks within 15-30 minutes of CJC-1295/Ipamorelin co-administration, with amplitude increases of 200-800% above baseline in study subjects
- In peer-reviewed studies, MK677 oral administration demonstrated sustained 24-hour IGF-1 elevation from the first dose, with peak effects at 2-4 hours post-administration
- Literature demonstrates rapid changes in sleep architecture with increased slow-wave sleep (stage 3-4) duration documented in published polysomnography studies
- Study participants reported enhanced dream vividness and improved morning alertness markers within the first 3-5 days of protocol initiation
IGF-1 Elevation & Recovery Enhancement
- Published research documented sustained IGF-1 elevation of 40-100% above baseline in study cohorts receiving combined GH secretagogue protocols
- In peer-reviewed studies, Ipamorelin demonstrated selective GH release without significant cortisol or prolactin elevation, distinguishing it from GHRP-6 and hexarelin in published comparative data
- Literature demonstrates enhanced exercise recovery markers including reduced muscle soreness duration and improved next-day performance metrics in published studies
- Study participants showed improved skin hydration and turgor markers, consistent with GH-mediated collagen synthesis increases documented in published data
Body Composition Initiation
- Published research observed initial changes in body composition markers including reduced skinfold measurements and increased lean mass indicators by week 4
- In peer-reviewed studies, MK677 demonstrated sustained lipolytic activity through GH-mediated pathways, with measurable reductions in truncal fat in published DEXA data
- Literature demonstrates increased nitrogen retention markers indicating anabolic signaling in skeletal muscle tissue in published studies
- Study cohorts reported enhanced exercise capacity with improved strength endurance markers as documented in published performance assessments
Connective Tissue & Joint Support
- Published research documented GH-mediated increases in collagen synthesis markers including procollagen type I and type III N-terminal peptides in study populations
- In peer-reviewed studies, elevated IGF-1 levels demonstrated support of cartilage proteoglycan synthesis and joint tissue integrity in published orthopedic literature
- Literature demonstrates measurable improvements in tendon and ligament health markers in study participants with prior connective tissue concerns
- Study participants reported reduced joint discomfort and improved mobility metrics as documented in published quality-of-life assessments
Advanced Body Recomposition
- Published research observed significant body recomposition with concurrent fat mass reduction and lean mass increase in study cohorts receiving combined secretagogue protocols
- In peer-reviewed studies, sustained IGF-1 elevation demonstrated dose-dependent effects on muscle protein synthesis rates as measured by stable isotope tracer methodologies
- Literature demonstrates improvements in visceral adipose tissue markers beyond what would be expected from GH-only approaches in published combination studies
- Study participants showed measurable improvements in hair quality, nail growth rate, and skin thickness markers consistent with sustained GH elevation in published data
Protocol Completion & Sustained GH Axis Optimization
- Published research documented maintained GH axis sensitivity without significant desensitization at 12-week protocol endpoints using pulsatile secretagogue approaches
- In peer-reviewed studies, body composition changes including reduced fat mass and increased lean mass persisted through the final assessment in published data
- Literature demonstrates that triple-secretagogue approaches engaging GHRH, ghrelin, and oral GH pathways simultaneously produced superior outcomes to single-compound protocols
- Study participants showed sustained improvements across sleep quality, recovery, body composition, and skin/connective tissue markers at protocol completion
Published Research
Peer-reviewed studies supporting this compound combination
Prolonged stimulation of growth hormone release by CJC-1295, a long-acting analog of growth-hormone-releasing hormone
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt R — Journal of Clinical Endocrinology & Metabolism, 2006
Published data demonstrated CJC-1295 produced dose-dependent GH elevations with mean IGF-1 increases of 36-105% sustained for 6-8 days following a single administration.
PMID: 16352683
Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. — European Journal of Endocrinology, 1998
In peer-reviewed research, Ipamorelin demonstrated the most selective GH secretion profile of any ghrelin-mimetic, with published data showing no significant changes in cortisol, prolactin, or ACTH levels.
PMID: 9916868
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
Murphy MG, Plunkett LM, Gertz BJ, et al. — Journal of Clinical Endocrinology & Metabolism, 1998
Literature demonstrates MK677 reversed nitrogen wasting and produced sustained GH/IGF-1 elevation over 24-hour periods in published clinical studies, with significant lean mass preservation.
PMID: 9435507
Two-year effects of GH-releasing hormone (GHRH) on body composition in older adults
Veldhuis JD, Patrie JT, Frick K, Weltman JY, Weltman A — Journal of Clinical Endocrinology & Metabolism, 2005
Published studies observed that GHRH-analog stimulation produced significant reductions in visceral fat and increases in lean body mass over extended administration periods in older adult cohorts.
PMID: 15998770
What Researchers Track
Common measurements and biomarkers for this protocol type
Reconstitution & Handling
Water Volume
2 mL bacteriostatic water per CJC-1295 and Ipamorelin vial; MK677 is oral capsule form
Concentration
CJC-1295: 2.5 mg/mL; Ipamorelin: 2.5 mg/mL; MK677: oral 25 mg capsule (no reconstitution)
Storage
Refrigerate peptide vials at 2-8°C after reconstitution. Stable for 28 days. MK677 capsules store at room temperature. Do not freeze peptides.
What the Research Shows
Peer-reviewed findings on each compound and their complementary mechanisms
Research shows CJC-1295 (no DAC) stimulates pulsatile growth hormone release from the anterior pituitary, mimicking physiological secretion patterns (PMID: 16352683).
Studies demonstrate Ipamorelin selectively amplifies GH pulses without significantly affecting cortisol or prolactin levels — a cleaner profile than earlier GH secretagogues (PMID: 9849822).
MK677 (Ibutamoren) research shows sustained elevation of growth hormone and IGF-1 levels over 24-hour periods through oral ghrelin mimetic activity (PMID: 9467542).
Published data suggests these three compounds engage different receptor systems (GHRH, ghrelin, and GHS receptors), producing a synergistic GH response in research models.
Research Dosing Reference
Dosing ranges cited in published studies — 8-12 weeks (cycle 8 on / 4 off) research protocol
CJC 1295 (no DAC)
Ipamorelin
MK677
Research Protocol Notes
CJC-1295 and Ipamorelin are best combined together in the same injection. Published protocols reference evening administration to coincide with the nocturnal GH pulse. MK677 is taken orally. Studies note fasting windows of 2 hours pre- and 30 minutes post-injection for optimal GH response.
What's in This Kit
3 peptides, each with individual COA documentation
CJC 1295 (without DAC)
$22.95Studied for pulsatile GH release mimicking natural rhythm
CJC 1295 (without DAC) is a research peptide in the growth hormone / gh secretagogues category. Mod GRF 1-29 is a modified 29-amino acid fragment of GHRH with four amino acid substitutions that prevent enzymatic degradation: D-Ala2 prevents DPP-IV cleavage, Gln8 prevents asparagine rearrangement, Ala15 enhances bioactivity, and Leu27 prevents methionine oxidation. MiPeptidos offers CJC 1295 (without DAC) in 3 sizes with 99.7% verified purity and full analytical documentation.
Ipamorelin
$13.95Studied for selective GH release without cortisol elevation
Ipamorelin is a research peptide in the growth hormone / gh secretagogues category. Ipamorelin is a highly selective growth hormone secretagogue that acts on the ghrelin/GHS receptor (GHSR) in the pituitary to stimulate pulsatile GH release. MiPeptidos offers Ipamorelin in 3 sizes with 99.7% verified purity and full analytical documentation.
MK677
$19.95Studied for sustained GH elevation with oral dosing
MK677 is a research peptide in the growth hormone / gh secretagogues category. MK-677 is an orally active, non-peptidic ghrelin receptor (GHSR-1a) agonist that mimics the GH-releasing activity of ghrelin. MiPeptidos offers MK677 in 1 sizes with 99.1% verified purity and full analytical documentation.
What Customers Say
Reviews from customers using peptides in this research kit
Frequently Asked Questions
Common questions about the GH Secretagogue Study Kit research kit
Related Research Kits
Tissue Repair Research Kit
The two most-cited tissue repair peptides studied together in published literature
2 peptides · Tissue Research
Incretin Pathway Comparator Kit
Single vs. dual receptor activation — the compounds from the STEP and SURPASS trials
2 peptides · Metabolic Research
Triple Incretin Comparator Kit
Single, dual, and triple agonists — the three compounds studied in STEP, SURPASS, and NEJM Phase 2 trials
3 peptides · Metabolic Research
Start Your Research
Get the complete GH Secretagogue Study Kit at $50.03 — save $6.82 versus purchasing each compound separately. Full COA documentation included with every vial.
Research Use Only. These products are intended for laboratory research purposes only. Not for human consumption. Dosing information is provided for research reference only. Consult a licensed healthcare provider before beginning any peptide protocol.